566 related items for PubMed ID: 7804123
1. Intensive therapy and autotransplantation in Hodgkin's disease.
Reece DE, Phillips GL.
Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
[Abstract] [Full Text] [Related]
2. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[Abstract] [Full Text] [Related]
3. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[Abstract] [Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB.
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[Abstract] [Full Text] [Related]
5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[Abstract] [Full Text] [Related]
6. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[Abstract] [Full Text] [Related]
7. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[Abstract] [Full Text] [Related]
8. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[Abstract] [Full Text] [Related]
9. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM, Loberiza FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM.
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[Abstract] [Full Text] [Related]
10. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
Cooney JP, Stiff PJ, Toor AA, Parthasarathy M.
Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
[Abstract] [Full Text] [Related]
11. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Brice P, Marolleau JP, Dombret H, Lepage E, Baruchel A, Adam M, Miclea JM, Sitthy X, Gisselbrecht C.
Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
[Abstract] [Full Text] [Related]
12. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H, Gruber A, Björkholm M, Svensson A, Hansson M.
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[Abstract] [Full Text] [Related]
13. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival.
Burns LJ, Daniels KA, McGlave PB, Miller WJ, Ramsay NK, Kersey JH, Weisdorf DJ.
Bone Marrow Transplant; 1995 Jul; 16(1):13-8. PubMed ID: 7581112
[Abstract] [Full Text] [Related]
14. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P.
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[Abstract] [Full Text] [Related]
15. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, Muhs A, Duerst RE, Abboud CN, Packman CH, DiPersio JF, Constine LS, Rowe JM, Liesveld JL.
Bone Marrow Transplant; 1998 Aug; 22(3):265-71. PubMed ID: 9720740
[Abstract] [Full Text] [Related]
16. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I.
Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
[Abstract] [Full Text] [Related]
17. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
Brice P, Gisselbrecht C, Ferme C, Lepage E, Baruchel A, Marolleau JP, Gerota O, Boiron M.
Nouv Rev Fr Hematol (1978); 1991 Apr; 33(3):267-72. PubMed ID: 1956765
[Abstract] [Full Text] [Related]
18. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J.
Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
[Abstract] [Full Text] [Related]
19. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH, Schwartzberg L, Li W, Hazelton B, West W.
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[Abstract] [Full Text] [Related]
20. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A.
Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
